.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Novartis
Cipla
Federal Trade Commission
UBS
Chinese Patent Office
Julphar
Queensland Health
Mallinckrodt
AstraZeneca

Generated: September 24, 2017

DrugPatentWatch Database Preview

Taro Company Profile

« Back to Dashboard

What is the competitive landscape for TARO, and what generic alternatives to TARO drugs are available?

TARO has two hundred and five approved drugs.

There are ten US patents protecting TARO drugs. There are three tentative approvals on TARO drugs.

There are sixty-two patent family members on TARO drugs in seventeen countries.

Summary for Applicant: Taro

Patents:10
Tradenames:105
Ingredients:89
NDAs:205
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm
CLORAZEPATE DIPOTASSIUM
clorazepate dipotassium
TABLET;ORAL075731-003Apr 27, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
FLUOCINONIDE
fluocinonide
GEL;TOPICAL074935-001Jul 29, 1997ABRXNoYes► Subscribe► Subscribe► Subscribe
Taro
CARVEDILOL
carvedilol
TABLET;ORAL077780-002Sep 5, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
FLUOROURACIL
fluorouracil
SOLUTION;TOPICAL076526-001Nov 5, 2003ATRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm Inds
LEVOCETIRIZINE DIHYDROCHLORIDE
levocetirizine dihydrochloride
SOLUTION;ORAL202673-001Jul 26, 2013AARXNoNo► Subscribe► Subscribe► Subscribe
Taro
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
SOLUTION;ORAL077009-001Nov 30, 2007AARXNoNo► Subscribe► Subscribe► Subscribe
Taro
TRIVAGIZOLE 3
clotrimazole
CREAM;VAGINAL021143-001Apr 12, 2000OTCNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
CLORAZEPATE DIPOTASSIUM
clorazepate dipotassium
TABLET;ORAL075731-002Apr 27, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
MELOXICAM
meloxicam
TABLET;ORAL078102-001Nov 7, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
HYDROCORTISONE
hydrocortisone
CREAM;TOPICAL088799-001Nov 9, 1984ATRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
Taro Pharms
PLIAGLIS
lidocaine; tetracaine
CREAM;TOPICAL021717-001Jun 29, 2006► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TARO drugs

Drugname Dosage Strength Tradename Submissiondate
desoximetasone
Topical Spray0.25%
TOPICORT
12/18/2013
malathion
Topical Lotion0.5%
OVIDE
3/16/2011

Premature patent expirations for TARO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Taro

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,886,038 Composition and method for treatment of psoriasis► Subscribe
8,039,657Process for preparing malathion for pharmaceutical use► Subscribe
8,206,727Oral suspension of prednisolone acetate► Subscribe
8,461,139Oral suspension of prednisolone acetate► Subscribe
6,355,258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form► Subscribe
8,957,238Process for preparing malathion for pharmaceutical use► Subscribe
8,536,155Process for preparing malathion for pharmaceutical use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Taro Drugs

Country Document Number Estimated Expiration
Japan2007126462► Subscribe
China101219108► Subscribe
New Zealand566117► Subscribe
World Intellectual Property Organization (WIPO)2007019184► Subscribe
Australia2006278620► Subscribe
South Korea20080044245► Subscribe
Israel187666► Subscribe
Japan2013014634► Subscribe
Hong Kong1036009► Subscribe
Germany60032021► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Taro Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C0022France► SubscribePRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
666Luxembourg► SubscribePRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C/GB01/012United Kingdom► SubscribePRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Federal Trade Commission
Healthtrust
Fish and Richardson
Julphar
US Army
Express Scripts
Cipla
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot